Aspen has announced the availability of Lilly’s tirzepatide, marketed globally as Mounjaro®, a therapeutic option available to physicians for the treatment of Type II diabetes.
Aspen announces local availability of Lilly’s Mounjaro

Aspen has announced the availability of Lilly’s tirzepatide, marketed globally as Mounjaro®, a therapeutic option available to physicians for the treatment of Type II diabetes.
Johannesburg, South Africa – Aspen Pharmacare, Africa’s largest pharmaceutical company, has announced continued humanitarian support to Ukraine, confirming further donations of critical care products to treat hospitalized patients who have been impacted by the ongoing conflict in that country. Stavros Nicolaou, Aspen Group Senior Executive Strategic Trade, said, “Aspen is highly sensitised to… Continue reading Aspen announces additional pharmaceutical donations for Ukranian patients
Johannesburg – JSE-listed Aspen Pharmacare Holdings Limited (APN), a global multinational specialty pharmaceutical company, has reported solid unaudited interim Group financial results for the six months ended 31 December 2023. SALIENT HIGHLIGHTS Revenue increased by 10% (2% in constant exchange rate (“CER”)) to R21,1 billion (December 2022: R19,2 billion) Normalised EBITDA increased by 2% (-5%… Continue reading Aspen building momentum with revenue up 10% to R21,1 billion